May 27, 2020 -- Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.
Under the agreement, Ajinomoto will provide drug product aseptic fill-finish services for Humanigen at its San Diego, CA facility.
Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody. The drug neutralizes a key cytokine in the initiation of a cytokine storm, a known factor in COVID-19 complications.
As part of the randomized, placebo-controlled, double-blinded phase III study, the drug is being administered in multiple locations across the U.S.